| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A868 | U.Penn. patent anti-PF4 Featured |
|
|
| A869 | Adakitug Featured | Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A870 | ABX-IL8 Featured | ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002). |
|
| A871 | Novimmune patent anti-CXCL9 Featured |
|
|
| A872 | Genzyme patent anti-CXCR3 Featured |
|
|
| A873 | Ulocuplumab Featured | Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. |
|
| A874 | Dana-Farber patent anti-CXCR4 Featured |
|
|
| A875 | SAR113244 Featured |
|
|
| A876 | Anti-DCBLD2/ESDN Antibody (FA19-1) Featured | The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A877 | INSERM patent anti-DC-SIGN Featured |
|
|
| A878 | U.Rochester patent anti-DC-STAMP Featured |
|
|
| A879 | Imperial College anti-DDR1 Featured |
|
|
| A880 | BHQ-880 Featured |
|
|
| DC60710 | Cysteine-vc-mmae Featured |
|
|
| A881 | LIV-1205 (CBA-1205) Featured |
|
|
| A882 | Navicixizumab Featured | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel.html" class="link-product" target="_blank"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. |
|
| A883 | Enoticumab Featured | Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively. |
|
| A884 | Smart Targeting patent anti-DLL4 Featured |
|
|
| A885 | Forerunner patent anti-DSG3 Featured |
|
|
| A886 | Centrose patent anti-dysadherin Featured |
|
|
| A887 | PF-06647263 Featured | PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody, ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts. |
|
| A888 | Parsatuzumab Featured | Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. |
|
| A889 | Centocor patent anti-CD147 Featured |
|
|
| A890 | Ags-16C3F Featured |
|
|
| A891 | TTX-030(Eltivutabart) Featured |
|
|
| A892 | Oportuzumab Featured |
|
|
| A893 | Adecatumumab Featured | Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. |
|
| A894 | Ifabotuzumab Featured |
|
|
| A895 | Genentech patent anti-EphB2 Featured |
|
|
| A896 | Morphosys patent anti-EphB4 Featured |
|
